Praxis Precision Medicines
Manufacturing · Massachusetts, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
99 High St Ste 30, Boston, Massachusetts...Phone Number
(617) 300-8460Website
www.praxismedicines.comRevenue
$7.5 MillionStock Symbol
PRAXIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Praxis Precision Medicines
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological and psychiatric disorders, using our understanding of shared biological targets and circuits in the brain. Praxis has established a broad portfolio with multiple programs, including product candidates across psychiatric disorders, movement disorders, epilepsy and other CNS indications, with three clinical-stage product candidates.Explore more
Praxis Precision Medicines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Praxis Precision Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Praxis Precision Medicines recently announced quarterly report
Product Launch: Get notified when Praxis Precision Medicines launches new products
Funding: Get notified immidiatlly once Praxis Precision Medicines has new funding data
Click to see if Praxis Precision Medicines had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Praxis Precision Medicines
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Praxis Precision Medicines is spiking on competitors!
Check if Praxis Precision Medicines has recently received funding, and reach out quickly before it becomes old news!
Praxis Precision Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined Praxis Precision Medicines as Masked Content
Find 2 more new buyers
Compare Similar Companies to Praxis Precision Medicines
Compare insights from companies similar to Praxis Precision Medicines, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Praxis Precision Medicines is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Praxis Precision Medicines is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Praxis Precision Medicines.
Praxis Precision Medicines financials insights
Gather financial insights about Praxis Precision Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Series C
$110M
Stock Offering
$190M
2021
Stock Offering
$91.3M
Praxis Precision Medicines Tech Stack
A closer look at the technologies used by Praxis Precision Medicines
Most Recent Scoops
Project
Praxis Precision Medicines has announced that the FDA completed a comprehensive BIMO inspection covering corporate and clinical operations, safety reporting, data integrity, and statistical analysis for both ulixacaltamide and relutrigine, concluding without any findings and with no Form 483 issued.
Compliance, Clinical Operations
Project
Praxis Precision Medicines has announced that the FDA deemed its additional clinical data submission for relutrigine a major amendment, extending the PDUFA target date to December 27 of this year, and confirmed that no advisory committee meeting is planned for the review.
Clinical Operations
Project
Praxis Precision Medicines has announced plans to launch relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathy (DEE), which, if approved, would be the first therapy for these conditions and would be eligible for a pediatric review voucher, with commercial and medical teams fully hired, the supply chain established, and a comprehensive patient support program in place.
Pharmaceuticals, Clinical Operations
Project
Praxis Precision Medicines has been given the Breakthrough Therapy Designation by the FDA for elsunersen for seizures associated with SCN2A developmental and epileptic encephalopathy (DEE) caused by gain-of-function variants, based on results from the EMBRAVE Part A study, marking the company's third such designation since July of last year.
Pharmaceuticals
Project
Pharmaceuticals
Praxis Precision Medicines News & Media
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on August 3, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 7,318 shares of its common stock to twenty-nine new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (thPraxis Precision Medicines to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
BOSTON, July 30, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report its financial results for the second quarter ended June 30, 2026 and provide a corporate update, before the financial markets open on Thursday, August 6, 2026.Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor
Collaboration aims to quickly enable ulixacaltamide to be delivered via active transdermal routePraxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on July 1, 2026, the Compensation Committee of Praxis’ Board of Directors granted restricted stock unit awards covering an aggregate of 951 shares of its common stock to five new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the 2024 Indu
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Praxis Precision Medicines
Sign Up For FreeTo access detailed company insights
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying insights from genetic epilepsies to both rare and more prevalent neurological and psychiatric disorders, using our und... Read More
